ClinicalTrials.gg
RecruitingNCT07418749Updated Apr 6, 2026

A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer

A Phase 3 interventional study of SHR-A2102 for Injection and Pemetrexed Disodium for Injection in Recurrent Cervical Cancer and Metastatic Cervical Cancer, sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd.. Recruiting at 1 site in China. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-06.

Sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
398
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 455 studies in Uterine Cervical Neoplasms with a site in China — 205 open to participants now, 240 under way, 35 of them phase 3. Uterine Cervical Neoplasms · China.

Planned enrollment
77th of 360
398 · median 90
Started
2026
with 24 others
Phase 3
56 of 455
21 open now
Primary completion
2027-12
later than 183 of 239 live
Registered
431st of 455
by date

Among the 455 studies in Uterine Cervical Neoplasms with a site in China, this one is the 77th largest by planned enrollment of the 360 interventional ones that give a count, is one of 25 that started in 2026, is one of 56 in phase 3, reaches primary completion later than 183 of the 239 other live ones, and was the 431st registered.

Uterine Cervical Neoplasms

2,368 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

205 of the 455 studies in Uterine Cervical Neoplasms with a site in China are open now. Recruiting first, the newest first:

199 more — sign in →

All 205 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 474 Uterine Cervical Neoplasms studies recruiting now, 244 (51%) set no upper age limit and 190 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 455 studies in Uterine Cervical Neoplasms with a site in China, or all of them as a file.
02

Study summary

The main objective of this study is to evaluate the efficacy of SHR-A2102 versus investigator's choice of chemotherapy in patients with platinum-based chemotherapy and PD-(L)1 inhibitor treatment failed recurrent or metastatic cervical cancer.

03

Conditions studied

  • Recurrent Cervical Cancer
  • Metastatic Cervical Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participate in the study voluntarily, sign the form.
  2. or cytologically confirmed cervical squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma that is deemed unsuitable for radical surgery and/or radical radiotherapy or chemoradiotherapy.
  3. Provide primary or tumor samples.
  4. At least one ( version 1.1).
  5. 0\~ 1.
  6. With adequate organ functions.
  7. Expected overall survival is ≥12 weeks.

Exclusion criteria

Exclusion Criteria:

  1. With known untreated or active central nervous system (CNS) tumor , or a history of or current .
  2. With symptomatic, poorly controlled, or moderate-to-severe pleural effusion, pericardial effusion, or ascites.
  3. With a history of or concurrent other malignant tumor(s).
  4. Participants with gastrointestinal perforation or fistula, urogenital fistula, or those at risk of fistula within 3 months prior to randomization.
  5. With known or suspected interstitial lung disease.
  6. With intestinal obstruction or signs/symptoms suggestive of intestinal obstruction within 3 months prior to randomization.
  7. With poorly controlled cardiac clinical symptoms or diseases.
  8. Experienced arterial/venous thromboembolic events within 3 months prior to randomization.
  9. With severe infections occurring within 1 month prior to randomization.
  10. With active (defined as positive hepatitis B surface antigen [HBsAg] test and hepatitis B virus [HBV] DNA ≥500 IU/mL at screening) or active (defined as positive hepatitis C virus antibody [HCV-Ab] test and detectable hepatitis C virus [HCV] RNA at screening).
  11. With active tuberculosis infection within 1 year prior to randomization, or a history of active tuberculosis infection more than 1 year ago without proper treatment.
  12. With a history of immunodeficiency, including a positive (HIV) test, other acquired or congenital immunodeficiency diseases, or a history of organ transplantation.
  13. Have received systemic anti-tumor therapy within 28 days prior to randomization.
  14. With uncontrolled psychiatric disorders, or known history of alcoholism, drug abuse, or substance dependence, incarceration, or other conditions that may affect the completion of study procedures.
  15. Any other condition that, in the judgment of the investigator, may increase the risk associated with study participation, interfere with the interpretation of study results, or make the participant unsuitable for the study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
398 participants (estimated)

Study arms

  • Experimental
    SHR-A2102 Group

    Participants receive SHR-A2102 for injection.

    Drug: SHR-A2102 for Injection

  • Active comparator
    The investigator's choice of chemotherapy Group

    Participants receive the investigator's choice of chemotherapy, with optional chemotherapeutic agents including: Pemetrexed Disodium for Injection, Gemcitabine Hydrochloride for Injection, Topotecan Hydrochloride for Injection, Paclitaxel for Injection (Albumin bound).

    Drug: Pemetrexed Disodium for Injection · Drug: Gemcitabine Hydrochloride for Injection · Drug: Topotecan Hydrochloride for Injection · Drug: Paclitaxel for Injection (Albumin bound)

Interventions

06

What researchers measure

Primary outcomes

  1. Overall survival (OS)

    OS is the time interval from the start of treatment to death due to any reason or lost of follow-up.

    Time frame: Up to 3 years.

Secondary outcomes

  1. Progression free survival (PFS)

    Assessed by the investigator according to RECIST 1.1 criteria.

    Time frame: Up to 3 years.

  2. Objective Response Rate (ORR)

    Assessed by the investigator according to RECIST 1.1 criteria.

    Time frame: Up to 3 years.

  3. Duration of response (DoR)

    Assessed by the investigator according to RECIST 1.1 criteria.

    Time frame: Up to 3 years.

  4. Disease control rate (DCR)

    Assessed by the investigator according to RECIST 1.1 criteria.

    Time frame: Up to 3 years.

  5. Adverse Events (AEs)

    Including incidence and grade, judged according to NCI-CTCAE V5.0 standards.

    Time frame: Up to 3 years.

  6. Serious Adverse Events (AEs)

    Including incidence and grade, judged according to NCI-CTCAE V5.0 standards.

    Time frame: Up to 3 years.

  7. Plasma concentrations of SHR-A2102

    Pharmacokinetics (PK) traits of SHR-A2102.

    Time frame: Up to 3 years.

  8. Plasma concentrations of SHR-A2102 metabolites

    Pharmacokinetics (PK) traits of SHR-A2102.

    Time frame: Up to 3 years.

  9. Incidence of Anti-Drug Antibody (ADA) of SHR-A2102

    Time frame: Up to 3 years.

  10. Incidence of Neutralizing Antibodies (Nab) of SHR-A2102

    Time frame: Up to 3 years.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Dec 2027, 21 months after the start.

Of 46 industry-sponsored phase 3 interventional studies under Uterine Cervical Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 55. This study's planned 21 months is below that.

Counting every sponsor, half of 99 studies reached it within 55 months; a quarter within 24 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2026
First posted
Feb 18, 2026
StartActual
Mar 30, 2026
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2028
Last update
Apr 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07418749
Responsible party
Sponsor
First posted
Feb 18, 2026
Start date
Mar 30, 2026
Primary completion
Dec 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Apr 6, 2026

Study contacts

Zhifei Lin
Contact
zhifei.lin.zl3@hengrui.com
+86-0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Notiretatug rezetecan

Start the discussion